Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study.

Mutations in the fibrillin-1 (FBN1) gene cause Marfan syndrome (MFS) and have been associated with a wide range of overlapping phenotypes. Clinical care is complicated by variable age at onset and the wide range of severity of aortic features. The factors that modulate phenotypical severity, both among and within families, remain to be determined. The availability of international FBN1 mutation Universal Mutation Database (UMD-FBN1) has allowed us to perform the largest collaborative study ever reported, to investigate the correlation between the FBN1 genotype and the nature and severity of the clinical phenotype. A range of qualitative and quantitative clinical parameters (skeletal, cardiovascular, ophthalmologic, skin, pulmonary, and dural) was compared for different classes of mutation (types and locations) in 1,013 probands with a pathogenic FBN1 mutation. A higher probability of ectopia lentis was found for patients with a missense mutation substituting or producing a cysteine, when compared with other missense mutations. Patients with an FBN1 premature termination codon had a more severe skeletal and skin phenotype than did patients with an inframe mutation. Mutations in exons 24-32 were associated with a more severe and complete phenotype, including younger age at diagnosis of type I fibrillinopathy and higher probability of developing ectopia lentis, ascending aortic dilatation, aortic surgery, mitral valve abnormalities, scoliosis, and shorter survival; the majority of these results were replicated even when cases of neonatal MFS were excluded. These correlations, found between different mutation types and clinical manifestations, might be explained by different underlying genetic mechanisms (dominant negative versus haploinsufficiency) and by consideration of the two main physiological functions of fibrillin-1 (structural versus mediator of TGF beta signalling). Exon 24-32 mutations define a high-risk group for cardiac manifestations associated with severe prognosis at all ages.

[1]  L. Peltonen,et al.  A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome. , 1996, Genomics.

[2]  H. Dietz,et al.  Targetting of the gene encoding fibrillin–1 recapitulates the vascular aspect of Marfan syndrome , 1997, Nature Genetics.

[3]  Uta Francke,et al.  Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. , 2002, American journal of human genetics.

[4]  A. De Paepe,et al.  Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. , 2001, Archives of internal medicine.

[5]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[6]  R. Pyeritz,et al.  Marfan syndrome: current and future clinical and genetic management of cardiovascular manifestations. , 1993, Seminars in thoracic and cardiovascular surgery.

[7]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[8]  G. Pals,et al.  Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome , 2004, Human mutation.

[9]  Bruce Bennetts,et al.  Detection of thirty novel FBN1 mutations in patients with Marfan syndrome or a related fibrillinopathy , 2004, Human mutation.

[10]  H. Firth,et al.  Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype? , 2003, Human molecular genetics.

[11]  U. Francke,et al.  Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. , 1999, American journal of human genetics.

[12]  D. Judge,et al.  Marfan's syndrome , 2005, The Lancet.

[13]  H. Dietz,et al.  Expression of a mutant human fibrillin allele upon a normal human or murine genetic background recapitulates a Marfan cellular phenotype. , 1995, The Journal of clinical investigation.

[14]  I. Campbell,et al.  Solution Structure of a Pair of Calcium-Binding Epidermal Growth Factor-like Domains: Implications for the Marfan Syndrome and Other Genetic Disorders , 1996, Cell.

[15]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[16]  Thierry Soussi,et al.  UMD (Universal Mutation Database): 2005 update , 2005, Human mutation.

[17]  U. Francke,et al.  Mutant fibrillin-1 monomers lacking EGF-like domains disrupt microfibril assembly and cause severe marfan syndrome. , 1996, Human molecular genetics.

[18]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[19]  E. Engvall,et al.  Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils , 1986, The Journal of cell biology.

[20]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[21]  C. Hayward,et al.  A novel mutation in the fibrillin gene (FBN1) in familial arachnodactyly. , 1994, Molecular and cellular probes.

[22]  H. Dietz,et al.  Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. , 1995, Human molecular genetics.

[23]  A. Munnich,et al.  In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome , 2003, Journal of medical genetics.

[24]  Jessica Geubtner,et al.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. , 2004, The Journal of clinical investigation.

[25]  L. Peltonen,et al.  A novel mutation of the fibrillin gene causing ectopia lentis. , 1994, Genomics.

[26]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[27]  P. Handford.  Fibrillin-1, a calcium binding protein of extracellular matrix. , 2000, Biochimica et biophysica acta.

[28]  N L Harris,et al.  Splice junctions, branch point sites, and exons: sequence statistics, identification, and applications to genome project. , 1990, Methods in enzymology.

[29]  P. Handford,et al.  Defective secretion of recombinant fragments of fibrillin-1: implications of protein misfolding for the pathogenesis of Marfan syndrome and related disorders. , 2003, Human molecular genetics.

[30]  H. Dietz,et al.  Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. , 1993, Genomics.

[31]  L. Peltonen,et al.  Sensitivity of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome and related conditions , 2002, Journal of medical genetics.

[32]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[33]  Flemming Skovby,et al.  TGGE screening of the entire FBN1 coding sequence in 126 individuals with marfan syndrome and related fibrillinopathies , 2002, Human mutation.

[34]  Marvin B. Shapiro,et al.  RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. , 1987, Nucleic acids research.

[35]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[36]  C. Kielty,et al.  Fibrillin-1 regulates the bioavailability of TGFβ1 , 2007, The Journal of cell biology.

[37]  P. Robinson,et al.  Mutations of FBN1 and genotype–phenotype correlations in Marfan syndrome and related fibrillinopathies , 2002, Human mutation.

[38]  D. Milewicz,et al.  A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. , 1995, The Journal of clinical investigation.

[39]  D. Sillence,et al.  International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986. , 1988, American journal of medical genetics.

[40]  J. Coselli,et al.  Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. , 1996, Circulation.

[41]  P. Byers,et al.  Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene. , 1996, American journal of medical genetics.

[42]  D. Apple,et al.  Current concepts of ocular manifestations in Marfan syndrome. , 2006, Survey of ophthalmology.

[43]  Gabor Matyas,et al.  Update of the UMD‐FBN1 mutation database and creation of an FBN1 polymorphism database , 2003, Human mutation.

[44]  L. Tavazzi,et al.  Identification of sixty‐two novel and twelve known FBN1 mutations in eighty‐one unrelated probands with Marfan syndrome and other fibrillinopathies , 2005, Human mutation.

[45]  P. Robinson,et al.  Novel exon skipping mutation in the fibrillin‐1 gene: Two ‘hot spots’ for the neonatal Marfan syndrome , 1999, Clinical genetics.

[46]  S. Henikoff,et al.  Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R E Pyeritz,et al.  Revised diagnostic criteria for the Marfan syndrome. , 1996, American journal of medical genetics.

[48]  K. Rommel,et al.  Identification of 29 novel and nine recurrent fibrillin‐1 (FBN1) mutations and genotype–phenotype correlations in 76 patients with Marfan syndrome , 2005, Human mutation.

[49]  Yusuke Nakamura,et al.  Heterozygous TGFBR2 mutations in Marfan syndrome , 2004, Nature Genetics.